Companies › IBRX

IMMUNITYBIO INC (IBRX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001326110 · EDGAR filings · Updated 2026-07-06

IMMUNITYBIO INC (IBRX) has reported institutional ownership of 17.0%, with 385 institutional managers holding positions valued at $1.36B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-07-06 — Insider transaction reported (Form 4)
• 2026-07-06 — Insider transaction reported (Form 4)
• 2026-07-02 — Notice of proposed sale filed (Form 144)
• 2026-07-01 — Insider transaction reported (Form 4)
• 2026-07-01 — Notice of proposed sale filed (Form 144)
• 2026-06-30 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, IMMUNITYBIO INC has 385 institutional holders and institutional ownership of 17.0%.

Insider activity

Insiders reported 33 transactions (0 buys, 8 sells) across 7 reporting insiders, with a net reported value of −$4.47M.

Data flags from SEC filings

Related companies

BICARA THERAPEUTICS INC (BCAX) · KALVISTA PHARMACEUTICALS INC (KALV) · PROGYNY INC (PGNY) · QUIDELORTHO CORP (QDEL) · HEALTHCARE SVCS GROUP INC (HCSG) · AVEANNA HEALTHCARE HLDGS INC (AVAH)